Flerie AB (OSTO:FLERIE) Research & Development: kr0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:FLERIE Flerie AB OSTO:FLERIE
26 GF Score
Price kr20.50
! 2 Warning Signs
View Full Analysis

What is Flerie AB Research & Development?

Flerie AB OSTO:FLERIE 26 Research & Development is kr0.00 Mil as of Jun. 2026. GuruFocus rates OSTO:FLERIE with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Flerie AB's Research & Development for the three months ended in Jun. 2026 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was kr0.00 Mil.

Flerie AB  (OSTO:FLERIE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Flerie AB Research & Development Related Terms

Flerie AB Research & Development Historical Data

* Premium members only.

The historical data trend for Flerie AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Flerie AB Research & Development Chart

Flerie AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Flerie AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:FLERIE
26GF Score
Flerie AB OSTO:FLERIE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Flerie AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
Flerie AB (OSTO:FLERIE) has a Research & Development of kr0.00 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Flerie AB and its competitors.
Is Flerie AB's Research & Development too high?
Flerie AB's current Research & Development is kr0.00 Mil. Overall, Flerie AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's Research & Development compare to VRTX and REGN?
Flerie AB's Research & Development of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Flerie AB and its competitors. Flerie AB's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (OSTO:FLERIE) has a current Research & Development of kr0.00 Mil. The current Research & Development is kr0.00 Mil. Flerie AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Flerie AB (OSTO:FLERIE), the current Research & Development is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Flerie AB Business Description

Other Exchanges 1NP1:Germany
Address Skeppsbron 16, Stockholm, SWE, 111 30
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
26GF Score

Get the complete analysis for OSTO:FLERIE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.50
Price